Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring
- 주제(키워드) COVID-19 , investigational medication , SARS-CoV-2 , severe acute respiratory syndrome
- 주제(기타) Pharmacology & Pharmacy
- 설명문(일반) [Kang, Ji Eun; Rhie, Sandy Jeong] Ewha Womans Univ, Coll Pharm, Seoul, South Korea; [Kang, Ji Eun] Natl Med Ctr, Dept Pharm, Seoul, South Korea; [Rhie, Sandy Jeong] Ewha Womans Univ, Grad Sch Pharmaceut Sci, Seoul, South Korea
- 등재 SCIE, SCOPUS
- OA유형 Green Published
- 발행기관 WILEY
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000174966
- 본문언어 영어
- Published As http://dx.doi.org/10.1111/jcpt.13199
- PubMed https://pubmed.ncbi.nlm.nih.gov/32524645
초록/요약
What is known and Objective Understanding investigational medications is important. Many older drugs are being investigated for repurposing against COVID-19. We comment on various drugs currently undergoing such trials to optimize their safe use. Comment We describe medications used during early COVID-19 outbreaks in South Korea, focusing on practice aspects including the method of drug administration, drug formulation, patient-monitoring for adverse reactions and drug interactions informed by our experience during the 2015 outbreak of Middle East respiratory syndrome (MERS). We comment on hydroxychloroquine, chloroquine, lopinavir/ritonavir with zinc supplement, remdesivir, tocilizumab, ciclesonide, niclosamide and high-dose intravenous immunoglobulin (IVIG). What is new and conclusion Effective therapies are urgently needed to manage COVID-19, and existing drugs such as antivirals and antimalarials are under investigation for repurposing to meet this need. This process requires up-to-date drug information to ensure optimum use, particularly safety and efficacy profiles of the medications, until convincing evidence is reported.
more